3SBio Inc. is a biotechnology company in the People's Republic of China with research and development, manufacturing, and marketing capabilities focusing on bio-pharmaceutical products. The Company recombinant, or genetically engineered, protein-based products and product candidates are designed to address markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Its principal products are EPIAO and TPIAO. In addition, it has two legacy products, Intefen and Inleusin; and an in-licensed product, Iron Sucrose Supplement. The Company focuses on its research and development efforts on both novel and validated protein-based therapeutics for the treatment of diseases in the areas of nephrology, oncology, supportive cancer care, inflammation and infectious diseases, and other selected areas. In May 2013, the Company merged with Decade Sunshine Limited and Decade Sunshine Merger Sub.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:SSRX
- CUSIP: N/A
- Web: N/A
- Trailing P/E Ratio:
- P/E Growth:
Frequently Asked Questions for 3SBio (NASDAQ:SSRX)
What is 3SBio's stock symbol?
3SBio trades on the NASDAQ under the ticker symbol "SSRX."
How were 3SBio's earnings last quarter?
3SBio Inc (NASDAQ:SSRX) announced its earnings results on Monday, March, 18th. The company reported $0.12 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.14 by $0.02. The business had revenue of $26.30 million for the quarter, compared to the consensus estimate of $25.63 million. View 3SBio's Earnings History.
Who are some of 3SBio's key competitors?
Some companies that are related to 3SBio include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Merck KGaA (MKGAY), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), ConvaTec Group PLC (CTEC), Mediclinic International PLC (MDC), Health Net (HNT), Patheon NV (PTHN), NMC Health PLC (NMC), Catalent (CTLT), VWR Corp (VWR), Cotiviti Holdings (COTV), Puma Biotechnology (PBYI) and Hikma Pharmaceuticals Plc (HIK).
How do I buy 3SBio stock?
Shares of 3SBio can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is 3SBio's stock price today?
MarketBeat Community Rating for 3SBio (NASDAQ SSRX)MarketBeat's community ratings are surveys of what our community members think about 3SBio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of 3SBio stock can currently be purchased for approximately $14.92.
Consensus Ratings for 3SBio (NASDAQ:SSRX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for 3SBio (NASDAQ:SSRX)
(Data available from 7/26/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|3/20/2017||Goldman Sachs Group, Inc. (The)||Upgrade||Neutral -> Buy||Low|
Earnings History for 3SBio (NASDAQ:SSRX)Earnings History by Quarter for 3SBio (NASDAQ SSRX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/18/2013||Q4 2012||$0.14||$0.12||$25.63 million||$26.30 million||View||Listen|
|11/12/2012||Q312||$0.29||$0.15||$28.18 million||$28.70 million||View||N/A|
Earnings Estimates for 3SBio (NASDAQ:SSRX)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for 3SBio (NASDAQ:SSRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for 3SBio (NASDAQ:SSRX)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for 3SBio (NASDAQ:SSRX)
Latest Headlines for 3SBio (NASDAQ:SSRX)
3SBio (SSRX) Chart for Wednesday, July, 26, 2017